The effectiveness of PSMA-targetinginhibitors, typically featuring central Lys-urea-Glu or Glu-urea-Glumotifs and various linker structures, is underscored by the FDA andEMA approvals of [177Lu]Lu-PSMA-617 (Pluvicto, Novartis,Basel, Switzerland) for PCa treatment in March and December 2022,respectively.4 Here, FOLH1 is linked to posterior cortical atrophy.